Skip to main content
. Author manuscript; available in PMC: 2014 May 1.
Published in final edited form as: Stroke. 2013 Mar 28;44(5):1410–1417. doi: 10.1161/STROKEAHA.113.678474

Figure 1.

Figure 1

Experimental designs. (A) Experiment 1 was designed to investigate the effect of the PAR-1 agonist, SFLLRN. (B) Experiment 2 was designed to evaluate the dose-dependent effect of SCH79797. (C) Experiment 3 was designed to show the effects of SCH79797 treatment. (D) Experiment 4 was designed to explore the mechanism of SCH79797 treatment. IP, intraperitoneally injection; IV, intravenously injection; IF, immunofluorescence staining; WB, Western blot.